texas oncology more breakthroughs. more victories

Share:

 
 

Austin North Research and Clinical Trials

Austin North participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Austin North Suite 300

Biliary Cancer

STAR Infigratinib vs Gem/Cis Cholangio

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301) Read More

Phase: III

Cervical Cancer

Ph2 Cervical 2L (RaPiDS)

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034(anti-PD-1) as a Monotherapy or Combination Therapy with AGEN1884(anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer(Second Line) - RaPiDS (C-750-01/GOG-3028) Read More

Phase: II

Endometrial Cancer

Ph 2 Nira + TSR-042 Plt Rst Ovarian

3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE) Read More

Phase: II

Ph3 TSR-042+car-pac vs plac+car-pac endo

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB (TSR-042) PLUS CARBOPLATIN-PACLITAXEL VERSUS PLACEBO PLUS CARBOPLATIN-PACLITAXEL IN PATIENTS WITH RECURRENT OR PRIMARY ADVANCED ENDOMETRIAL CANCER (RUBY) (4010-03-001 / ENGOT EN-6 / GOG-3031) Read More

Phase: III

Fallopian Tube Cancer

Ph 2 Nira + TSR-042 Plt Rst Ovarian

3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE) Read More

Phase: II

Ph3 TSR-042, Niraparib Ovarian FIRST

3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER Read More

Phase: III

Lung Cancer

STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789) Read More

Phase: III

Lymphomas

STAR BV in older pts w/1L cHL or PTCL

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above Read More

Phase: II

Ovarian Cancer

Ph 2 Nira + TSR-042 Plt Rst Ovarian

3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE) Read More

Phase: II

Ph3 TSR-042, Niraparib Ovarian FIRST

3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER Read More

Phase: III

Peritoneal Cancer

Ph 2 Nira + TSR-042 Plt Rst Ovarian

3000-02-006: A Phase 2 Open-label, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients with Platinum-Resistant Ovarian Cancer (MOONSTONE) Read More

Phase: II

Ph3 TSR-042, Niraparib Ovarian FIRST

3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER Read More

Phase: III

Solid Tumors

STAR Ph2 Pemigatinib Solids FGFR

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Read More

Phase: II

Urothelial Cancer

STAR Ph3 FGFR erdafitinib urothelial

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) Read More

Phase: III